10 June 2013
EMA/PRAC/352733/2013
Pharmacovigilance Risk Assessment Committee (PRAC)

Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda of meeting on 10-13 June 2013

Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.
The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.
The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.
RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)
(Item 6 of the PRAC agenda)

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7051
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.
PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections
(Item 8 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

Chair: June Raine – Vice-Chair: Almath Spooner

10 June 2013, 13:00 – 19:00, room 3/A

11 June 2013, 08:30 – 19:00, room 3/A

12 June 2013, 08:30 – 19:00, room 3/A

13 June 2013, 08:30 – 16:00, room 3/A

Organisational, regulatory and methodological matters (ORGAM)

27 June 2013, 10:30-12:30, room 6/A, via teleconference

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

1.2. Adoption of the agenda of the PRAC meeting on 10-13 June 2013

Status: for adoption

Document: PRAC Agenda Rev.3 due for publication on 10 June 2013

1.3. Minutes of the previous PRAC meeting on 13-16 May 2013

Status: for adoption

Document: PRAC Final Minutes due for publication by 21 June 2013

2. EU Referral Procedures for Safety Reasons: Urgent EU Procedures

2.1. Newly triggered procedures

None

2.2. Ongoing Procedures

None

2.3. Procedures for finalisation

2.3.1. **Flupirtine** (NAP)

- Review of the benefit-risk balance of flupirtine-containing medicines following notification by Germany of a referral under Article 107i of Directive 2001/83/EC

Status: *for discussion and agreement of a recommendation to CMDh*

Regulatory details:

PRAC Rapporteur: Margarida Guimarães (PT)
PRAC Co-Rapporteur: Martin Huber (DE)

2.4. Planned public hearings

None

3. EU Referral Procedures for Safety Reasons: Other EU Referral Procedures

3.1. Newly triggered Procedures

None

3.2. Ongoing Procedures

3.2.1. Combined hormonal contraceptives:
desogestrel, **gestodene, norgestimate**, **etonogestrel, drospirenone**, **dienogest**, **chlormadinone**, **norgestimate** (NAP), **nomegestrol acetate / estradiol – IOA** (CAP), **ZOELY** (CAP), **norelgestromin / ethinylestradiol** - **EVRA** (CAP)

- Review of the benefit-risk balance of combined hormonal contraceptives following notification by France of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

***Status**: for discussion*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)
PRAC Co-Rapporteur: Evelyne Falip (FR)

3.3. Procedures for finalisation

3.3.1. Codeine (NAP)

- Review of the risk-benefit balance of codeine-containing medicines following the notification by the United Kingdom of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

***Status**: for discussion and agreement of a recommendation to CMDh*

Regulatory details:

PRAC Rapporteur: Dolores Montero Corominas (ES)
PRAC Co-Rapporteur: Julie Williams (UK)

3.3.2. Diclofenac (NAP)

- Review of the benefit-risk balance of diclofenac-containing medicines following notification by the United Kingdom of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

***Status**: for discussion and agreement of a recommendation to CMDh*

Regulatory details:

PRAC Rapporteur: Doris Stenver (DK)
PRAC Co-Rapporteur: Julie Williams (UK)

3.3.3. Hydroxyethyl starch (**HES**), **solutions for infusion** (NAP)

- Review of the benefit-risk balance of HES-containing products following notification by Germany of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

***Status**: for discussion and agreement of a recommendation to CMDh*

Regulatory details:

PRAC Rapporteur: Qun-Ying Yue (SE)
PRAC Co-Rapporteur: Martin Huber (DE)

3.4. Article 5(3) of Regulation (EC) No 726/2004 as amended: PRAC advice on CHMP request

3.4.1. GLP-1 based therapy products (glucagon-like-peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors) (CAP)

- Review of findings on pancreatic risks following notification by the European Medicines Agency (EMA) under Article 5(3) of Regulation (EC) 726/2004

***Status**: for information*

Regulatory details:

PRAC Rapporteur: Qun-Ying Yue (SE)
PRAC Co-Rapporteur: Menno van der Elst (NL)

4. Signals assessment and prioritisation[1]

4.1. New signals detected from EU spontaneous reporting systems

4.1.1. Adalimumab – HUMIRA (CAP)

- Signal of immune reconstitution inflammatory syndrome (IRIS)

***Status**: for discussion*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

4.1.2. Capecitabine – XELODA (CAP)

- Signal of acute renal failure

***Status**: for discussion*

Regulatory details:

PRAC Rapporteur: Martin Huber (DE)

4.1.3. Infliximab – REMICADE (CAP)

- Signal of immune reconstitution inflammatory syndrome (IRIS)

***Status**: for discussion*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

[1] Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products, including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required.

4.1.4. **Lenograstim** (NAP)

- Signal of (systemic) capillary leak syndrome (CLS)

***Status**: for discussion*

Regulatory details:

PRAC Rapporteur: *To be appointed*

4.2. New signals detected from other sources

4.2.1. **Orlistat - ALLI** (CAP), **XENICAL** (CAP)

- Signal of inhibition of carboxylesterase-2 from an in vitro study

***Status**: for discussion*

Regulatory details:

PRAC Rapporteur: *To be appointed*

4.3. Signals follow-up and prioritisation

4.3.1. **Etanercept – ENBREL** (CAP)

- Signal of dermatomyositis

***Status:** for discussion*

Regulatory details:

PRAC Rapporteurs: Julie Williams (UK)

4.3.2. **Exenatide – BYDUREON** (CAP), **BYETTA** (CAP); **liraglutide – VICTOZA** (CAP)

- Signal of gastrointestinal stenosis and obstruction

***Status:** for discussion*

Regulatory details:

PRAC Rapporteurs: Qun-Ying Yue (SE); Menno van der Elst (NL)

4.3.3. **Leflunomide – ARAVA** (CAP)

- Signal of myositis

***Status:** for discussion*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

4.3.4. Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) – PANDEMRIX (CAP)

- Signal of narcolepsy: further information following conclusion of the data review of Pandemrix and narcolepsy under Article 20 of Regulation (EC) No 726/2004

Status: *for discussion*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)

4.3.5. Somatropin – NUTROPINAQ (CAP), OMNITROPE (NAP)

- Signal of convulsions

Status: *for discussion*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

4.3.6. Tiotropium bromide (NAP)

- Signal of anaphylactic reaction

Status*: for discussion*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

4.3.7. Tramadol (NAP)

- Signal of hypoglycaemia

Status: *for discussion*

Regulatory details:

PRAC Rapporteur: Evelyne Falip (FR)

4.3.8. Zolpidem (NAP)

- Signal of next-morning impaired mental alertness, including impaired driving ability

Status: *for discussion*

Regulatory details:

PRAC Rapporteur: Carmela Macchiarulo (IT)

5. Risk Management Plans

5.1. Medicines in the pre-authorisation phase

5.1.1. Alogliptin

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.2. Alogliptin, metformin

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.3. Alogliptin, pioglitazone

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.4. Bedaquiline

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.5. Canagliflozin

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.6. Cholic acid

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.7. Dabrafenib

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.8. Elvitegravir

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.9. Esomeprazole

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.10. Fenofibrate, simvastatin

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.11. Indacaterol, glycopyrronium bromide

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.12. Infliximab

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.13. Levodopa, carbidopa, entacapone

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.14. Lidocaine, prilocaine

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.15. Mercaptine

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.16. Regorafenib

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

5.1.17. Riociguat

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.18. Trametinib

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.19. Trastuzumab emtasine

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.20. Vortioxetine

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.2. Medicines already authorised

RMP in the context of a PSUR procedure

5.2.1. Bosentan – TRACLEER (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Evelyne Falip (FR)

See also 6.1.4.

5.2.2. Denosumab – PROLIA (CAP), XGEVA (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

See also 6.1.7.

5.2.3. Erlotinib – TARCEVA (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Doris Stenver (DK)

See also 6.1.9.

5.2.4. Indacaterol – HIROBRIZ BREEZHALER (CAP), ONBREZ BREEZHALER (CAP), OSLIF BREEZHALER (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Line Michan (DK)

See also 6.1.11.

5.2.5. Ivabradine – **CORLENTOR** (CAP), **PROCORALAN** (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Menno van der Elst (NL)

See also 6.1.12.

5.2.6. Rilpivirine – **EDURANT** (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

See also 6.1.20.

5.2.7. Tafamidis – **VYNDAQEL** (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Evelyne Falip (FR)

See also 6.1.27.

RMP in the context of a variation

5.2.8. Aflibercept – **EYLEA** (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

***Status:** for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Evelyne Falip (FR)

5.2.9. Bevacizumab – **AVASTIN** (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

***Status:** for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Doris Stenver (DK)

5.2.10. Bortezomib – VELCADE (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Carmela Macchiarulo (IT)

5.2.11. Dexamethasone – OZURDEX (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)

5.2.12. Golimumab – SIMPONI (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

5.2.13. Golimumab – SIMPONI (CAP)

- Evaluation of an RMP in the context of a variation, line extension

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

5.2.14. Paliperidone – INVEGA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Qun-Ying Yue (SE)

5.2.15. Panitumumab – VECTIBIX (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Julia Dunne (UK)

5.2.16. Voriconazole – VFEND (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

5.2.17. Ulipristal – ESMYA (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

RMP in the context of a renewal of the marketing authorisation, conditional renewal or annual reassessment

See Filgrastim Hexal, Zarzio under 8.1.5. ; Evicel under 8.1.7.

RMP in the context of a stand-alone RMP procedure

5.2.18. Boceprevir – VICTRELIS (CAP)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Isabelle Robine (FR)

5.2.19. Deferasirox – EXJADE (CAP)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Isabelle Robine (FR)

5.2.20. Human normal immunoglobulin – PRIVIGEN (CAP)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

5.2.21. Ibandronic acid – IASIBON (CAP)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Doris Stenver (DK)

5.2.22. Ibandronic acid – IBANDRONIC ACID SANDOZ (CAP)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Doris Stenver (DK)

5.2.23. Interferon alfa-2b – INTRONA (CAP)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Jean-Michel Dogné (BE)

5.2.24. Raltegravir – ISENTRESS (CAP)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)

6. Assessment of Periodic Safety Update Reports (PSURs)

6.1. Evaluation of PSUR procedures[2]

6.1.1. Antithrombin alfa – ATRYN (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Isabelle Robine (FR)

[2] Where a regulatory action is recommended (variation, suspension or revocation of the terms of Marketing Authorisation(s)), the assessment report and PRAC recommendation are transmitted to the CHMP for adoption of an opinion. Where PRAC recommends the maintenance of the terms of the marketing authorisation(s), the procedure finishes at the PRAC level.

6.1.2. Apixaban – **ELIQUIS** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

6.1.3. Boceprevir – **VICTRELIS** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Isabelle Robine (FR)

6.1.4. Bosentan – **TRACLEER** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Evelyne Falip (FR)

See also 5.2.1.

6.1.5. Bromfenac – **YELLOX** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Line Michan (DK)

6.1.6. Cotexin, piperaquine phosphate – **EURARTESIM** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)

6.1.7. Denosumab – **PROLIA** (CAP), **XGEVA** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

See also 5.2.2.

6.1.8. Doxorubicin – MYOCET (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

6.1.9. Erlotinib – TARCEVA (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Doris Stenver (DK)

See also 5.2.3.

6.1.10. Filgrastim – NIVESTIM (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Kirsti Villikka (FI)

6.1.11. Indacaterol – HIROBRIZ BREEZHALER (CAP), **ONBREZ BREEZHALER** (CAP), **OSLIF BREEZHALER** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Line Michan (DK)

See also 5.2.4.

6.1.12. Ivabradine – **CORLENTOR** (CAP), **PROCORALAN** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Menno van der Elst (NL)

See also 5.2.5.

6.1.13. Levetiracetam – **KEPPRA** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Jean-Michel Dogné (BE)

6.1.14. Mercaptamine bitartrate – **CYSTAGON** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Dolores Montero Corominas (ES)

6.1.15. Mercaptopurine – **XALUPRINE** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

6.1.16. Natalizumab – **TYSABRI** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

6.1.17. Nepafenac – **NEVANAC** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Dolores Montero Corominas (ES)

6.1.18. Ofatumumab – ARZERRA (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Doris Stenver (DK)

6.1.19. Pegvisomant – SOMAVERT (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Evelyne Falip (FR)

6.1.20. Rilpivirine – EDURANT (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

See also 5.2.6.

6.1.21. Rituximab – MABTHERA (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Doris Stenver (DK)

6.1.22. Rotavirus vaccine, **live**, **oral – ROTATEQ** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Julia Dunne (UK)

6.1.23. Sapropterin – KUVAN (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Almath Spooner (IE)

6.1.24. Saquinavir – INVIRASE (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Harald Herkner (AT)

6.1.25. Saxagliptin, **metformin – KOMBOGLYZE** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Menno van der Elst (NL)

6.1.26. Stiripentol – DIACOMIT (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)

6.1.27. Tafamidis – VYNDAQEL (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Evelyne Falip (FR)

See also 5.2.7.

6.1.28. Temoporfin – **FOSCAN** (CAP)

- Evaluation of a PSUR procedure

***Status**: for discussion and agreement of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

6.2. Follow-up to PSUR procedures[3]

6.2.1. Agalsidase alfa – **REPLAGAL** (CAP)

- Evaluation of a follow-up to a PSUR procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

6.2.2. Azilsartan medoxomil – **EDARBI** (CAP), **IPREZIV** (CAP)

- Evaluation of a follow-up to a PSUR procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Menno van der Elst (NL)

6.2.3. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) – **PREVENAR 13** (CAP)

- Evaluation of a follow-up to a PSUR procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Qun-Ying Yue (SE)

[3] Follow up procedures as per the conclusions of PSUR procedures, assessed outside next PSUR procedures

7. Post-authorisation Safety Studies (PASS)

7.1. Protocols of post-authorisation safety studies

7.1.1. **Adalimumab – HUMIRA** (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

7.1.2. **Aflibercept – EYLEA** (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Evelyne Falip (FR)

7.1.3. **Aflibercept – ZALTRAP** (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

7.1.4. **Asenapine – SYCREST** (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)

7.1.5. **Florbetapir (18F) – AMYVID** (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Martin Huber (DE)

7.1.6. Florbetapir (18F) – AMYVID (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Martin Huber (DE)

7.1.7. Human normal immunoglobulin – PRIVIGEN (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

7.1.8. Human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) – CERVARIX (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Jean-Michel Dogné (BE)

7.1.9. Ivacaftor – KALYDECO (CAP)

- PRAC consultation on PASS protocol conducted pursuant an obligation imposed in accordance with Article 21a and 22a of Directive 2001/83/EC

***Status:** for discussion and agreement of PRAC letter of endorsement/objection/notification*

Regulatory details:

PRAC Rapporteur: Miguel-Angel Macia (ES)

7.1.10. Loxapine – ADASUVE (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

7.1.11. Mirabegron – BETMIGA (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Miguel-Angel Macia (ES)

7.1.12. Nalmefene – SELINCRO (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Martin Huber (DE)

7.1.13. Romiplostim – NPLATE (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Dolores Montero Corominas (ES)

7.2. Results of post-authorisation safety studies

None

See Finasteride under 11.3.1.

8. Renewals of the Marketing Authorisation, Conditional Renewals and Annual Reassessments

8.1.1. Aliskiren, hydrochlorothiazide – RASILEZ HCT (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Carmela Macchiarulo (IT)

8.1.2. **Brentuximab vedotin – ADCETRIS** (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

8.1.3. **Crizotinib – XALKORI** (CAP)

- PRAC consultation on a conditional renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Isabelle Robine (FR)

8.1.4. **Darunavir – PREZISTA** (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

8.1.5. **Filgrastim – FILGRASTIM HEXAL** (CAP), **ZARZIO** (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)

8.1.6. **Histamine dihydrochloride – CEPLENE** (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Almath Spooner (IE)

8.1.7. **Human fibrinogen**, **human thrombin – EVICEL** (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

8.1.8. Idursulfase – ELAPRASE (CAP)

- PRAC consultation on an annual reassessment procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Julia Dunne (UK)

8.1.9. Irbesartan – IFIRMASTA (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Dolores Montero Corominas (ES)

8.1.10. Olanzapine – ZYPADHERA (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Terhi Lehtinen (FI)

8.1.11. Pramipexole – PRAMIPEXOLE TEVA (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Qun-Ying Yue (SE)

8.1.12. Saproterin – KUVAN (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Almath Spooner (IE)

8.1.13. Ziconotide – PRIALT (CAP)

- PRAC consultation on an annual reassessment procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Jean-Michel Dogné (BE)

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

9.1.1. Risk-based programme for routine pharmacovigilance inspections of Marketing Authorisation Holders of Centrally Authorised Products for human use

***Status**: for discussion and agreement of the programme*

9.2. On-going or concluded pharmacovigilance inspection

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

10. Other Safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation (MA)

10.1.1. Cetuximab – ERBITUX (CAP)

- PRAC consultation on a safety-related variation, upon CHMP request

***Status:** for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

10.1.2. Ruxolitinib – JAKAVI (CAP)

- PRAC consultation on a safety-related variation, upon CHMP request

***Status:** for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

10.2. Timing and message content in relation to MS safety announcements

None

10.3. Other requests

11. Other Safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

None

11.2. Renewals of the marketing authorisation

None

11.3. Other requests

11.3.1. **Finasteride** (NAP)

- PRAC consultation on PASS results, upon Member State's request

Status: *for discussion and agreement of advice to Member States*

Regulatory details:

Lead member: Ulla Wändel Liminga (SE)

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

12.2. Pharmacovigilance audits and inspections

12.2.1. Pharmacovigilance Systems and their Quality Systems

None

12.2.2. Pharmacovigilance Inspections

None

12.2.3. Pharmacovigilance Audits

None

12.3. Periodic Safety Update Reports & Union Reference Date (EURD) List

12.3.1. Periodic Safety Update Reports

None

12.3.2. PSURs Repository

None

12.3.3. Union Reference Date List

12.3.3.1. Consultation on the draft List, version June 2013

Status: *for discussion and agreement of the list*

12.4. Signal Management

12.4.1. Signal Management

- Feedback from Signal Management Review Technical (SMART) Working Group

Status: *for information*

12.5. Adverse Drug Reactions reporting and additional reporting

12.5.1. Management and Reporting of Adverse Reactions to Medicinal Products

None

12.5.2. Additional Monitoring

None

12.5.3. List of Product under Additional Monitoring

12.5.3.1. Consultation on the draft List, version June 2013

Status: *for discussion and agreement of the list*

12.6. EudraVigilance Database

12.6.1. Activities related to the confirmation of full functionality

None

12.6.2. Changes to EudraVigilance Database and functional specifications

None

12.7. Risk Management Plans and Effectiveness of risk Minimisations

12.7.1. Risk Management Systems

None

12.7.2. Tools, Educational Materials and Effectiveness Measurement for Risk Minimisation

None

12.8. Post-authorisation Safety Studies

12.8.1. Post-Authorisation Safety Studies

12.8.2. Patient Registries

- Proposal to initiate the process of encouraging and supporting joint disease based-registries

***Status**: for discussion*

12.9. Community Procedures

12.9.1. Referral Procedures for Safety Reasons

None

12.10. Risk communication and Transparency

12.10.1. Public Participation in Pharmacovigilance

None

12.10.2. Safety Communication

None

12.11. Continuous pharmacovigilance

12.11.1. Continuous Pharmacovigilance, Ongoing Benefit-Risk Evaluation, Regulatory Status and Planning of Public Communication

None

12.11.2. Incident Management

None

12.12. Interaction with EMA Committees and Working Parties

12.12.1. Committees

None

12.12.2. Human Scientific Committees Working Party with Healthcare Professionals' Organisations (HCPWP) and Patients' and Consumers' Working Party (PCWP)

- Nomination of PRAC representative at the HCPWP and PCWP

12.13. Interaction within the EU regulatory network

None

12.14. Contacts of the PRAC with external parties and interaction of the EMA with interested parties

12.14.1. Guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)

None

12.14.2. Novel influenza strain (H7N9) in humans

- Preparatory activities

***Status**: for discussion*

12.14.3. Medication errors workshop

- Outcome of workshop and implementation plan

***Status**: for discussion*

12.14.4. Others

None

13. Any other business

None